RESPONSE TO FINAL OFFICE ACTION PAGE 2
APPL. No.: 10/598,048 GROUP ART UNIT: 1612

DOCKET NO.: HMV-091.02

IN THE CLAIMS

Claims 1-270 (canceled)

271. (previously presented) A method of treating an ophthalmologic disorder characterized by an

accumulation of retinotoxic compounds in the cells of the retinal pigment epithelium in a

subject comprising administering to the subject a pharmaceutically acceptable amount of

fenretinide or a pharmaceutically acceptable salt thereof.

272. (previously presented) The method of claim 271, wherein fenretinide inhibits, antagonizes,

or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a

rod photoreceptor cell.

273. (previously presented) The method of claim 271, wherein the ophthalmologic disorder is

macular degeneration.

274. (withdrawn) The method of claim 271, wherein the ophthalmologic disorder is Stargardt's

disease.

275. (withdrawn) The method of claim 271, wherein the ophthalmologic disorder is lipofuscin

accumulation.

Claims 276-279 (canceled)